Response to 'Paricalcitol for pre-dialysis stages of chronic kidney disease'
Respuesta a "Paricalcitol en la enfermedad renal crónica en etapas anteriores a la diálisis"
Read
7003
Timeswas read the article
2126
Total PDF
4877
Total HTML
Share statistics
array:21 [ "pii" => "X2013251412000793" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2012.Jan.11337" "estado" => "S300" "fechaPublicacion" => "2012-03-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:251-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4018 "formatos" => array:3 [ "EPUB" => 282 "HTML" => 3121 "PDF" => 615 ] ] "Traduccion" => array:1 [ "es" => array:17 [ "pii" => "X0211699512000796" "issn" => "02116995" "doi" => "10.3265/Nefrologia.pre2012.Jan.11337" "estado" => "S300" "fechaPublicacion" => "2012-03-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia. 2012;32:251-2" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 6008 "formatos" => array:3 [ "EPUB" => 287 "HTML" => 5080 "PDF" => 641 ] ] "es" => array:9 [ "idiomaDefecto" => true "titulo" => "Respuesta a "Paricalcitol en la enfermedad renal crónica en etapas anteriores a la diálisis"" "tienePdf" => "es" "tieneTextoCompleto" => "es" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "251" "paginaFinal" => "252" ] ] "titulosAlternativos" => array:1 [ "en" => array:1 [ "titulo" => "Response to ¿Paricalcitol for pre-dialysis stages of chronic kidney disease¿" ] ] "contieneTextoCompleto" => array:1 [ "es" => true ] "contienePdf" => array:1 [ "es" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "José G. Hervás-Sánchez" "autores" => array:1 [ 0 => array:2 [ "nombre" => "José G." "apellidos" => "Hervás-Sánchez" ] ] ] ] ] "idiomaDefecto" => "es" "Traduccion" => array:1 [ "en" => array:9 [ "pii" => "X2013251412000793" "doi" => "10.3265/Nefrologia.pre2012.Jan.11337" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "en" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000793?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512000796?idApp=UINPBA000064" "url" => "/02116995/0000003200000002/v0_201502091353/X0211699512000796/v0_201502091354/es/main.assets" ] ] "itemSiguiente" => array:17 [ "pii" => "X2013251412000785" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2011.Dec.11299" "estado" => "S300" "fechaPublicacion" => "2012-03-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:252" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4649 "formatos" => array:3 [ "EPUB" => 309 "HTML" => 3666 "PDF" => 674 ] ] "en" => array:9 [ "idiomaDefecto" => true "titulo" => "Salicylate poisoning" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:1 [ "paginaInicial" => "252" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Intoxicación por salicilatos" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Santiago Nogué Xarau, Santiago Nogué-Xarau, Antonio Dueñas Laita, Antonio Dueñas-Laita" "autores" => array:4 [ 0 => array:2 [ "nombre" => "Santiago" "apellidos" => "Nogué Xarau" ] 1 => array:2 [ "nombre" => "Santiago" "apellidos" => "Nogué-Xarau" ] 2 => array:2 [ "nombre" => "Antonio" "apellidos" => "Dueñas Laita" ] 3 => array:2 [ "nombre" => "Antonio" "apellidos" => "Dueñas-Laita" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699512000788" "doi" => "10.3265/Nefrologia.pre2011.Dec.11299" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512000788?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000785?idApp=UINPBA000064" "url" => "/20132514/0000003200000002/v0_201502091616/X2013251412000785/v0_201502091617/en/main.assets" ] "itemAnterior" => array:17 [ "pii" => "X2013251412000808" "issn" => "20132514" "doi" => "10.3265/Nefrologia.pre2011.Dec.11312" "estado" => "S300" "fechaPublicacion" => "2012-03-01" "documento" => "article" "licencia" => "http://www.elsevier.com/open-access/userlicense/1.0/" "subdocumento" => "fla" "cita" => "Nefrologia (English Version). 2012;32:250-1" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:2 [ "total" => 4017 "formatos" => array:3 [ "EPUB" => 290 "HTML" => 3128 "PDF" => 599 ] ] "en" => array:9 [ "idiomaDefecto" => true "titulo" => "Paricalcitol for pre-dialysis stages of chronic kidney disease" "tienePdf" => "en" "tieneTextoCompleto" => "en" "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "250" "paginaFinal" => "251" ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Paricalcitol en la enfermedad renal crónica en etapas anteriores a la diálisis" ] ] "contieneTextoCompleto" => array:1 [ "en" => true ] "contienePdf" => array:1 [ "en" => true ] "autores" => array:1 [ 0 => array:2 [ "autoresLista" => "Jaume Almirall, M. Isabel Bolos" "autores" => array:2 [ 0 => array:2 [ "nombre" => "Jaume" "apellidos" => "Almirall" ] 1 => array:2 [ "nombre" => "M. Isabel" "apellidos" => "Bolos" ] ] ] ] ] "idiomaDefecto" => "en" "Traduccion" => array:1 [ "es" => array:9 [ "pii" => "X0211699512000800" "doi" => "10.3265/Nefrologia.pre2011.Dec.11312" "estado" => "S300" "subdocumento" => "" "abierto" => array:3 [ "ES" => true "ES2" => true "LATM" => true ] "gratuito" => true "lecturas" => array:1 [ "total" => 0 ] "idiomaDefecto" => "es" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X0211699512000800?idApp=UINPBA000064" ] ] "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000808?idApp=UINPBA000064" "url" => "/20132514/0000003200000002/v0_201502091616/X2013251412000808/v0_201502091617/en/main.assets" ] "en" => array:10 [ "idiomaDefecto" => true "titulo" => "Response to 'Paricalcitol for pre-dialysis stages of chronic kidney disease'" "tieneTextoCompleto" => true "paginas" => array:1 [ 0 => array:2 [ "paginaInicial" => "251" "paginaFinal" => "252" ] ] "autores" => array:1 [ 0 => array:3 [ "autoresLista" => "José G. Hervás-Sánchez" "autores" => array:1 [ 0 => array:4 [ "nombre" => "José G." "apellidos" => "Hervás-Sánchez" "email" => array:1 [ 0 => "jhervas@ugr.es" ] "referencia" => array:1 [ 0 => array:2 [ "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] ] "afiliaciones" => array:1 [ 0 => array:3 [ "entidad" => "Servicio de Nefrología, Hospital Clínico Universitario de Granada, Granada, " "etiqueta" => "<span class="elsevierStyleSup">a</span>" "identificador" => "affa" ] ] ] ] "titulosAlternativos" => array:1 [ "es" => array:1 [ "titulo" => "Respuesta a "Paricalcitol en la enfermedad renal crónica en etapas anteriores a la diálisis"" ] ] "textoCompleto" => "<p class="elsevierStylePara"><span class="elsevierStyleBold">To the Editor,</span></p><p class="elsevierStylePara">We were very interested by the comments submitted by Drs Almirall and Bolos from <span class="elsevierStyleItalic">Corporació Sanitària i Universitària Parc Taulí </span>at Hospital de Sabadell (Barcelona), regarding our article on the effectiveness of paricalcitol for controlling hyperparathyroidism in early stages of chronic kidney disease,<span class="elsevierStyleSup">1</span> and first of all, we would like to thank them for their input.</p><p class="elsevierStylePara">They are completely correct in pointing out that we did not highlight the relevant fact that the level of 25-OH vitamin D was deficient in our patient population. We did not call attention to this fact because we are currently undertaking a larger study on vitamin D deficiency, including more than 300 patients with chronic kidney disease (CKD) in pre-dialysis stages, and given the scope and length of this article, we decided — perhaps erroneously — to leave it for a later occasion.</p><p class="elsevierStylePara">However, we would like to comment on some of the ideas expressed by these authors, with a particular view to compensate for the lack of information on vitamin D that they detected.</p><p class="elsevierStylePara">First of all, levels of both native vitamin D and calcitriol are low in CKD, and the complex relationships between them are still largely unclear. This is also reported by Dr Dusso in a recent article<span class="elsevierStyleSup">2</span> regarding both the calcium-parathyroid hormone-bone axis and their so-called pleiotropic effects due to vitamin D receptors being widespread. It is interesting to note that CKD patients may have a vitamin D deficiency of up to 80%, even though the conversion to 25-OH vitamin D by 25-hydroxylase (CYP2R1) occurs in the liver and not the kidney.<span class="elsevierStyleSup">3</span></p><p class="elsevierStylePara">In addition, the cause of 25-OH D deficiency is unclear. Hypotheses include low exposure to sunlight, deficient intake of provitamin and many more. We know that calcidiol binds to DBP (vitamin D binding protein), is filtered by the glomerulus, and is later endocytosed via megalin into proximal tubule cells. It has been demonstrated that disease progression in renal patients is accompanied by a decrease in megalin. At the same time, there may be a loss of DBP and even 25-OH vitamin D in proteinuric kidney disease. Furthermore, 25-OH D deficiency is very common in nephrotic syndrome, even when renal function is normal. Similarly, in early stages of kidney disease, increased FGF 23 may inhibit activity by renal 1-alpha hydroxylase and increase catabolism of 1,25-D and 25-OH D, thereby activating production of the enzyme that breaks down both forms (24-hydroxylase). It has even been observed that calcium deficiency promotes depletion of 25-OH D. In addition, 1,25-D itself stimulates hepatic inactivation of 25-OH D.<span class="elsevierStyleSup">4</span> We therefore completely agree with treating and maintaining proper 25-OH D levels from stage 1-2 kidney disease, as recommended by the S.E.N. 2011 guidelines.</p><p class="elsevierStylePara">However, a different issue is whether vitamin D supplements alone are sufficient to control hyperparathyroidism. It seems obvious that proper levels of 25-OH D, the substrate for calcitriol synthesis, must be reached in order to promote the synthesis process and prevent hyperparathyroidism. Nevertheless, it is unlikely that vitamin D supplements are enough to compensate for low VDR expression in tissues. It has been reported that using ergocalciferol as a supplement reduces PTH only in those patients with serum levels of 25 OH-D below 30ng/ml.<span class="elsevierStyleSup">2</span> It has also been reported that only 50% of patients with stage 3 or 4 CKD who take vitamin D supplements see an increase in 25-OH D levels.<span class="elsevierStyleSup">5</span></p><p class="elsevierStylePara">In any case, we feel that the matter is open for debate. Preclinical and clinical trials with sufficient prospective power should be undertaken in order to determine the benefit in simultaneously providing vitamin D supplements and active metabolites of vitamin D. However, although Dr Dusso warns of the risk of toxicity associated with this combination and it does not seem recommendable at present.<span class="elsevierStyleSup">2</span></p><p class="elsevierStylePara">Lastly, regarding the economic savings associated with using a certain treatment or another (which is certainly a hot topic today), our attention was called to the last sentence in the letter, which reminds us that the most important consideration is the benefit to the patient. Public prices are established by the authorities which regulate and shape healthcare policy, and not by doctors. We believe that our role is to make efficient use of the resources which the Health System puts at our disposal and choose the best option for each patient and each specific situation. This will be the case as long as we are permitted to make choices, because given the current climate, it is likely that only one drug will be provided for treating a condition in the near future, and that it will be chosen by political figures and not doctors. This will effectively put a stop to the debate.</p><p class="elsevierStylePara"> </p><p class="elsevierStylePara"><span class="elsevierStyleBold">Conflicts of interest</span></p><p class="elsevierStylePara"> </p><p class="elsevierStylePara">The authors affirm that they have no conflicts of interest related to the content of this article.</p>" "pdfFichero" => "P1-E534-S3461-A11337-EN.pdf" "tienePdf" => true "bibliografia" => array:2 [ "titulo" => "Bibliography" "seccion" => array:1 [ 0 => array:1 [ "bibliografiaReferencia" => array:5 [ 0 => array:3 [ "identificador" => "bib1" "etiqueta" => "1" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Hervás JG, Prados MD, Polo A, Cerezo S. Efectividad del tratamiento con paricalcitol por vía oral en pacientes con enfermedad renal crónica en etapas anteriores a la diálisis. Nefrologia 2011;31(6):697-706. <a href="http://www.ncbi.nlm.nih.gov/pubmed/22130286" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 1 => array:3 [ "identificador" => "bib2" "etiqueta" => "2" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Dusso A, Tokumoto M. Defective renal maintenance of the vitamin D endocrine system impairs vitamina D renoprotection: a downward spiral in kidney diseases. Kidney Int 2011;79:715-29. <a href="http://www.ncbi.nlm.nih.gov/pubmed/21270766" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 2 => array:3 [ "identificador" => "bib3" "etiqueta" => "3" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Al-Badr W, Martin KJ. Vitamin D and kidney disease. Clin J Am Soc Nephrol 2008;3:1555-60. <a href="http://www.ncbi.nlm.nih.gov/pubmed/18450926" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 3 => array:3 [ "identificador" => "bib4" "etiqueta" => "4" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Rojas-Rivera J, De La Piedra C, Ramos A, Ortiz A, Egido J. The expanding spectrum of biological actions of vitamin D.\u{A0}Nephrol Dial Transplant 2010;25:2850-65. <a href="http://www.ncbi.nlm.nih.gov/pubmed/20525641" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] 4 => array:3 [ "identificador" => "bib5" "etiqueta" => "5" "referencia" => array:1 [ 0 => array:3 [ "referenciaCompleta" => "Al-Aly Z, Qazi RA, Gonzalez EA, et al. Changes in serum 25 hydroxyvitamin D and plasma PTH levels following treatment with ergocalciferol in patients with CKD. Am J Kidney Dis 2007;50:59-68. <a href="http://www.ncbi.nlm.nih.gov/pubmed/17591525" target="_blank">[Pubmed]</a>" "contribucion" => array:1 [ 0 => null ] "host" => array:1 [ 0 => null ] ] ] ] ] ] ] ] ] "idiomaDefecto" => "en" "url" => "/20132514/0000003200000002/v0_201502091616/X2013251412000793/v0_201502091617/en/main.assets" "Apartado" => array:4 [ "identificador" => "35439" "tipo" => "SECCION" "en" => array:2 [ "titulo" => "Letters to the Editor - Comments on published articles" "idiomaDefecto" => true ] "idiomaDefecto" => "en" ] "PDF" => "https://static.elsevier.es/multimedia/20132514/0000003200000002/v0_201502091616/X2013251412000793/v0_201502091617/en/P1-E534-S3461-A11337-EN.pdf?idApp=UINPBA000064&text.app=https://revistanefrologia.com/" "EPUB" => "https://multimedia.elsevier.es/PublicationsMultimediaV1/item/epub/X2013251412000793?idApp=UINPBA000064" ]
| Year/Month | Html | Total | |
|---|---|---|---|
| 2024 November | 7 | 8 | 15 |
| 2024 October | 65 | 41 | 106 |
| 2024 September | 68 | 25 | 93 |
| 2024 August | 66 | 50 | 116 |
| 2024 July | 43 | 25 | 68 |
| 2024 June | 38 | 35 | 73 |
| 2024 May | 50 | 25 | 75 |
| 2024 April | 42 | 40 | 82 |
| 2024 March | 28 | 23 | 51 |
| 2024 February | 28 | 27 | 55 |
| 2024 January | 29 | 25 | 54 |
| 2023 December | 12 | 24 | 36 |
| 2023 November | 37 | 37 | 74 |
| 2023 October | 31 | 29 | 60 |
| 2023 September | 20 | 30 | 50 |
| 2023 August | 40 | 17 | 57 |
| 2023 July | 30 | 29 | 59 |
| 2023 June | 27 | 21 | 48 |
| 2023 May | 40 | 30 | 70 |
| 2023 April | 13 | 9 | 22 |
| 2023 March | 34 | 24 | 58 |
| 2023 February | 18 | 20 | 38 |
| 2023 January | 18 | 19 | 37 |
| 2022 December | 38 | 30 | 68 |
| 2022 November | 19 | 34 | 53 |
| 2022 October | 20 | 31 | 51 |
| 2022 September | 44 | 20 | 64 |
| 2022 August | 43 | 54 | 97 |
| 2022 July | 24 | 34 | 58 |
| 2022 June | 28 | 34 | 62 |
| 2022 May | 33 | 27 | 60 |
| 2022 April | 24 | 40 | 64 |
| 2022 March | 31 | 32 | 63 |
| 2022 February | 25 | 40 | 65 |
| 2022 January | 33 | 26 | 59 |
| 2021 December | 30 | 35 | 65 |
| 2021 November | 37 | 32 | 69 |
| 2021 October | 24 | 38 | 62 |
| 2021 September | 37 | 34 | 71 |
| 2021 August | 29 | 38 | 67 |
| 2021 July | 35 | 31 | 66 |
| 2021 June | 16 | 20 | 36 |
| 2021 May | 28 | 28 | 56 |
| 2021 April | 64 | 59 | 123 |
| 2021 March | 29 | 29 | 58 |
| 2021 February | 23 | 15 | 38 |
| 2021 January | 31 | 17 | 48 |
| 2020 December | 12 | 13 | 25 |
| 2020 November | 24 | 15 | 39 |
| 2020 October | 24 | 17 | 41 |
| 2020 September | 8 | 4 | 12 |
| 2020 August | 37 | 10 | 47 |
| 2020 July | 17 | 8 | 25 |
| 2020 June | 20 | 11 | 31 |
| 2020 May | 27 | 9 | 36 |
| 2020 April | 17 | 15 | 32 |
| 2020 March | 33 | 10 | 43 |
| 2020 February | 22 | 18 | 40 |
| 2020 January | 28 | 17 | 45 |
| 2019 December | 31 | 14 | 45 |
| 2019 November | 26 | 15 | 41 |
| 2019 October | 11 | 8 | 19 |
| 2019 September | 19 | 29 | 48 |
| 2019 August | 18 | 9 | 27 |
| 2019 July | 9 | 23 | 32 |
| 2019 June | 21 | 12 | 33 |
| 2019 May | 14 | 14 | 28 |
| 2019 April | 31 | 26 | 57 |
| 2019 March | 23 | 13 | 36 |
| 2019 February | 15 | 17 | 32 |
| 2019 January | 25 | 15 | 40 |
| 2018 December | 59 | 43 | 102 |
| 2018 November | 82 | 17 | 99 |
| 2018 October | 53 | 23 | 76 |
| 2018 September | 74 | 10 | 84 |
| 2018 August | 69 | 21 | 90 |
| 2018 July | 50 | 16 | 66 |
| 2018 June | 45 | 17 | 62 |
| 2018 May | 51 | 17 | 68 |
| 2018 April | 54 | 7 | 61 |
| 2018 March | 47 | 15 | 62 |
| 2018 February | 57 | 10 | 67 |
| 2018 January | 51 | 10 | 61 |
| 2017 December | 44 | 15 | 59 |
| 2017 November | 43 | 8 | 51 |
| 2017 October | 37 | 18 | 55 |
| 2017 September | 29 | 12 | 41 |
| 2017 August | 21 | 8 | 29 |
| 2017 July | 36 | 9 | 45 |
| 2017 June | 36 | 6 | 42 |
| 2017 May | 32 | 18 | 50 |
| 2017 April | 31 | 18 | 49 |
| 2017 March | 15 | 6 | 21 |
| 2017 February | 20 | 10 | 30 |
| 2017 January | 27 | 17 | 44 |
| 2016 December | 54 | 4 | 58 |
| 2016 November | 50 | 10 | 60 |
| 2016 October | 86 | 13 | 99 |
| 2016 September | 118 | 3 | 121 |
| 2016 August | 168 | 3 | 171 |
| 2016 July | 168 | 9 | 177 |
| 2016 June | 113 | 0 | 113 |
| 2016 May | 117 | 0 | 117 |
| 2016 April | 82 | 0 | 82 |
| 2016 March | 75 | 0 | 75 |
| 2016 February | 83 | 0 | 83 |
| 2016 January | 106 | 0 | 106 |
| 2015 December | 110 | 0 | 110 |
| 2015 November | 82 | 0 | 82 |
| 2015 October | 69 | 0 | 69 |
| 2015 September | 88 | 0 | 88 |
| 2015 August | 59 | 0 | 59 |
| 2015 July | 57 | 0 | 57 |
| 2015 June | 39 | 0 | 39 |
| 2015 May | 43 | 0 | 43 |
| 2015 April | 6 | 0 | 6 |
Show all
